TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or Type 2 diabetes mellitus.~* Patients with visual impairment due to focal or diffuse diabetic macular oedema (DMO), and not other causes, in at least one eye who are eligible for laser treatment in the opinion of the investigator.~* Best Corrected Visual Acuity between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximate Snellen equivalent of 20/32 to 20/320).~* Increased central retinal thickness which, in the opinion of the investigator, is due to DMO.~Exclusion Criteria:~* Concomitant conditions in the study eye that could prevent the improvement of visual acuity on study treatment.~* Active intraocular inflammation (grade trace or above) or infection in either eye at enrollment.~* History of uveitis in either eye at any time.~* Structural damage within 0.5 disc diameters of the centre of the macular in the study eye likely to preclude improvement in visual acuity following resolution of macular oedema.~* Planned medical or surgical intervention during the 18-month study period.~* Uncontrolled glaucoma in either eye at screening.~* Blood pressure systolic \> 160 mmHg or diastolic \> 100 mmHg at screening.~* Ocular conditions in the study eye that require chronic concomitant therapy with topical ocular or systemically administered corticosteroids.~* History of acute thromboembolic event within 4 months of screening.~* Untreated diabetes mellitus.~* Evidence of advanced, severe or unstable concomitant disease or its treatment which may interfere with evaluations or put the patient at special risk.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.5mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quartet Lead and Resynchronization Therapy Options III (QUARTO_III)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient that will be implanted with a Cardiac Resynchronization Therapy (CRT-D) with the MultiPoint Pacing (MPP) feature under the current Guidelines indications for CRT-D implant (including upgrades from single or dual chamber Defibrillator or Pacemaker).~* Patient that will be implanted with a Quartet Left Ventricular (LV) quadripolar lead.~* In sinus rhythm at baseline visit.~* Patients with Left Bundle Branch Block (LBBB)~* Must be willing and able to comply with study requirements.~* Older than 18 years~* Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form.~Exclusion Criteria:~* Already has a CRT device implanted.~* Myocardial Infarction or unstable angina within 40 days prior the enrollment.~* New York Heart Association (NYHA) Class IV~* Recent cardiac revascularization in the 4 weeks prior to enrollment.~* Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) in the 3 months prior the enrollment.~* Classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 12 months.~* Primary valvular disease requiring surgical intervention.~* Atrial Fibrillation (AF):~  * Persistent AF at the time of enrollment or 30 days prior the enrollment~ * Permanent AF not treated with Atrio-Ventricular node ablation within 2 weeks after the CRT-D implant~ * History or incidence of Paroxysmal or Persistent AF within 30 days prior the enrollment~* Patient for whom suitable Transthoracic echocardiographic images for determining the cardiac output (CO) and LV volumes cannot be obtained.~* Undergone a cardiac transplantation or being waiting for it~* Life expectancy \< 6 months~* Pregnancy or planning to become pregnant~* Unable to comply with the follow up schedule~* Currently participating in any other clinical investigation.-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPP ON (Type: EXPERIMENTAL): To activate the Multipoint Pacing (MPP) feature to ON in all patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Immunotherapy In Alternaria-Induced Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis~* Symptoms May-October~* Specific IgE to alternaria (skin test/radioallergosorbent \[RAST\] test)~* Age \>14~Exclusion Criteria:~* Sensitization to mites, parietaria, mugwort~* Pregnancy-lactation~* Malignancies~* Chronic systemic steroids~* Previous immunotherapy to alternaria

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SLIT (Type: EXPERIMENTAL): sublingual immunotherapy biologically standardized
- placebo (Type: PLACEBO_COMPARATOR): same preparation of SLIT without the allergen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has been diagnosed with RA~* Physician has decided, with the subject's consent, to begin treatment with infliximab~* Written informed consent form signed by both the subject and the physician.~Exclusion Criteria:~* Subjects who have previously been exposed to infliximab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RA Subjects/ Infliximab 3 mg/kg (Type: None): Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics \[SPC\] of Remicade®).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residence in the study site~* Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is \< 18 years)~Exclusion Criteria:~* Residence outside of in the study site~* Height ≤ 90 cm~* Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* Pregnancy~* Breast feeding if infant is within 1 week of birth~* Known allergy to the study drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single MDA (Type: ACTIVE_COMPARATOR): Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
- Repeated MDA (Type: EXPERIMENTAL): Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tobacco Dependence Treatment for Asian Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Korean-speaking Koreans who:~1. Are ages of 18 and older~2. Have been smoking at least 10 or more cigarettes on average per day for the past 30 days; AND~3. Are willing to quit smoking and receive NRT~Exclusion Criteria:~1. Inability to speak and understand Korean or English~2. Involvement in behavioral or other pharmacological smoking cessation programs~3. History of serious cardiac diseases and/or presence of skin diseases (see Human Subjects); OR~4. Pregnancy, lactation or plans to become pregnant in the next 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- deep cultural arm (Type: EXPERIMENTAL): deep cultural therapy
- standard arm (Type: ACTIVE_COMPARATOR): brief cessation counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing Genetic Education for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current Smoker~* Smoking ten or more cigarettes per day~* 19 years or older~* Intention of quitting smoking in the next month~* Agree to use two forms of acceptable birth control while using the nicotine replacement patch~Exclusion Criteria:~* Not currently seeking treatment for a mental disorder with psychotic symptoms~* Not currently pregnant nor nursing~* Not been recently diagnosed or currently affected with cancer or any other life-threatening illness~* No recent heart attack~* No history of high blood pressure or not currently receiving treatment to manage high blood pressure~* No history of an irregular heartbeat~* Not currently taking medications to help quit smoking (i.e. Chantix, Zyban or Wellbutrin, NRT)~* No history of adverse effects from using nicotine replacement patches~* Not currently experiencing serious pain or discomfort due to heart disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Genetic Education Session (GES) (Type: EXPERIMENTAL): The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
- Nutrition Education Session (NES) (Type: ACTIVE_COMPARATOR): The objective is to provide a control group that will received comparable attention as the experimental group by providing USDA approved nutritional information (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Hospitalized for episode of worsening heart failure as primary cause of admission or significant heart failure symptoms that develop during the hospitalization when the initial reason for admission was not heart failure.~* Systolic dysfunction (LVEF \< 40%) or heart failure symptoms in the setting of preserved systolic function (diastolic dysfunction).~Exclusion criteria:~* This study has no exclusion criteria.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed an asenapine 3-week study for the treatment of an acute manic or mixed episode and not had a major protocol violation.in the short term study (A7501004 or A7501005) that they completed.~Exclusion Criteria:~* Patients with unstable medical conditions or clinically significant laboratory abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Asenapine
- 2 (Type: ACTIVE_COMPARATOR): Olanzapine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renally impaired with a historical diagnosis of type 2 diabetes mellitus and is experiencing inadequate glycemic control on their current regime of diet and exercise or their antidiabetic therapy of metformin, TZD, SU, or any combination of these oral antidiabetic medications~* BMI \>/=20 kg/m2 and \</=45 kg/m2~* Fasting C-peptide \>/=0.8 ng/mL (\>/=0.26 nmol/L)~* HbA1c between 7.0% and 10.0%, inclusive.~Exclusion Criteria:~* History of cancer~* History of treated diabetic gastroparesis~* Current biliary disease or history of pancreatitis~* History of significant gastrointestinal surgery~* Recent clinically significant cardiovascular and/or cerebrovascular disease~* History of human immunodeficiency virus infection~* Abnormal liver function or acute symptomatic infection with hepatitis B or hepatitis C~* Female subject is pregnant (confirmed by laboratory testing), lactating, or \<6 weeks postpartum~* Known allergy to any GLP 1 analogue, sitagliptin, other study medications' excipients, excipients of albiglutide, or Baker's yeast~* Receipt of any investigational drug or sitagliptin within the 30 days or 5 half lives, whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albiglutide (Type: ACTIVE_COMPARATOR): albiglutide weekly subcutaneous injection + sitagliptin matching placebo
- sitagliptin (Type: ACTIVE_COMPARATOR): albiglutide matching placebo + sitagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women aged 47-53 years, being invited for their first breast screen, without a history of breast disease or malignancy, living in the London Borough of Hillingdon, were eligible for inclusion in the trial.~Exclusion Criteria:~Women with a history of breast disease, malignancy, bi-lateral mastectomy, or breast screen, aged over 54 years were not eligible for inclusion in the trial. Non-routine appointments, male appointments, and self referrals were also not eligible for inclusion.

- Gender: FEMALE
- Minimum Age: 47 Years
- Maximum Age: 53 Years
- Healthy Volunteers: t

Study Arms:
- No Text Message Reminder (Control) Arm (Type: NO_INTERVENTION): Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
- Text Message Reminder Arm (Type: EXPERIMENTAL): Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate-to-severe rosacea (as per the IGA score) on the proposed facial treatment area consisting of:~   1. At least 15 and not more than 75 facial papules and pustules, excluding lesions involving the eyes and scalp;~  2. No more than 2 nodules on the face.~2. Presence of or history of erythema and/or flushing on the face.~Exclusion Criteria:~1. Presence of any skin condition and/or Excessive facial hair, on the face that would interfere with the diagnosis or assessment of rosacea.~2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like facial edema.~3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of any other component of the formulation.~4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX103 1.5% (Type: EXPERIMENTAL): Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DMD patients age 7 years and older (and able to complete cardiac MRI without sedation) with preserved left ventricular (LV) systolic function and abnormal heart muscle by late post-gadolinium imaging (LGE)~Exclusion Criteria:~* renal insufficiency (GFR \<40 mL/min/m2)~* non-MR compatible implants (e.g. neurostimulator, AICD)~* severe claustrophobia~* allergy to gadolinium contrast~* prior use of or known allergy to epleronone~* use of potassium-sparing diuretics~* serum potassium level of \>5.0 mmol/L

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eplerenone (Type: ACTIVE_COMPARATOR): active study drug
- sugar pill (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete